J.P.
Celgene Corporation (NASDAQ:CELG) announced it has fulfilled the accelerated approval requirements for POMALYST® (pomalidomide) based on results from MM-003, an international phase III study …
Celgene Corporation (NASDAQ:CELG) announced that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in patients with Behçet’s disease were …
Celgene Corporation (NASDAQ:CELG) announced the election of Michael W. Bonney to its Board of Directors.
Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with …
In a research report published Friday, Canaccord Genuity analyst John Newman maintained a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target …
(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2014. For the fourth quarter of 2014, …
(BUSINESS WIRE)– Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency’s (EMA) Committee for …
(BUSINESS WIRE)– Celgene International Sàrl (NASDAQ:CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation …
(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) provided a business update as well as its preliminary 2014 results and financial outlook for 2015 and beyond …
